Glioblastoma brain tumors can have an unusual effect on the body's immune system, often causing a dramatic drop in the number of circulating T-cells that help drive the body's defenses. Where the T-cells go has been unclear, even as immunotherapies are increasingly employed to stimulate the body's natural ability to fight invasive tumors. Now researchers at Duke Cancer Institute have tracked the missing T-cells in glioblastoma patients. They found them
Study reveals an unexpected regulatory role for Nup210 in T cell homeostasis Nuclear pore complexes in the nuclear membrane not only control the transport of molecules into and out of the nucleus—they play an essential role in the survival of T cells. A new study by Sanford Burnham Prebys Medical Discovery Institute (SBP) researchers describes how a specific nuclear pore component is critical for the survival of circulating T cells.
More than seven years after the start of one of the first clinical trials of the immunotherapy drug nivolumab, researchers at the Johns Hopkins Kimmel Cancer Center report that the five-year survival estimate for a limited subset of people with advanced nonsmall cell lung cancer taking the drug is 16 percent, compared with a historical survival rate for that group of 1 to 4 percent. A summary of the trial